Atea Pharmaceuticals, Inc. (AVIR): R&D Expense
$148.02M
Year ended 2025-12-31
$155.45M
Trailing 12 months to 2026-06-30
+21.8%
3-year compound annual growth
+31.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $148.02M | +2.7% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $144.10M | +26.1% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $114.24M | +39.4% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $81.94M | -51.0% | 2024-02-28, From 2022-01-01 |
| 2021-12-31 | $167.21M | +339.7% | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | $38.02M | +273.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $10.17M | +52.4% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $6.67M | n/a | 2021-03-30, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $148.02M | +2.7% |
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $16.74M | -67.3% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $104.00M | -5.1% |
| Omeros Corp (OMER) | 2025-12-31 | $81.30M | -32.0% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $60.26M | +5.2% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $13.18M | -32.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $142.01M | -17.1% |
Compare AVIR, LBRX, ADCT, OMER side by side · Screen every company in Pharmaceutical Preparations ↗